Type 1 diabetes is a chronic autoimmune disease; after diagnosis, people with this condition require life-long insulin therapy. The identification of biomarkers to detect, at an early stage, who among those identified as being at high risk of Type 1 diabetes will go on to develop the condition would potentially allow intervention before depletion of the pancreatic β-cell population. It would also reduce the likelihood of presentation in ketoacidosis with its attendant risk, both acutely and in the longer term This article is protected by copyright. All rights reserved.
Dublin City University ->